Home
Storia in 1 fonti
More Data Support Trodelvy-Keytruda Combo in Triple-Negative Breast Cancer
ASCENT-04 analysis finds PFS2 advantage as an indicator of long-term clinical benefit
Raccontata da
medpagetoday.com
Timeline cronologica
- ·
Drug Combo for Lung Cancer Beats Pembrolizumab in First-Line Trial
Antibody-drug conjugate plus pembrolizumab superior to pembrolizumab alone in PD-L1 expressors
- ·
More Data Support Trodelvy-Keytruda Combo in Triple-Negative Breast Cancer
ASCENT-04 analysis finds PFS2 advantage as an indicator of long-term clinical benefit